In one aspect, the invention relates to pharmaceutical compositions and methods for treating a cancer comprising administration of an EGFR inhibitor and a MEK or MET inhibitor. In various aspects, the methods can comprise determination of increased levels of HGF, e.g., determining if a patient has an increased level of serum HGF. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
